CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. Between 75-95% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

OptimizeRx Q3 sales fall on contracted revenue; lowers annual revenue outlook

By Reuters News


Overview

  • Healthcare technology firm's Q3 revenue fell 17% yr/yr but beat analyst expectations

  • Q3 adjusted EPS and adjusted EBITDA both beat analyst expectations

  • Company updated 2026 revenue guidance to $87-$93 mln, citing lower contracted revenue


Outlook

  • Company updates 2026 revenue outlook to $87-$93 mln

  • Company maintains 2026 adjusted EBITDA guidance at $21-$25 mln

  • Company sees renewed Q4 spending from a previously significant customer and pent-up demand for 2027 RFP season


Result Drivers

  • MARGIN EXPANSION - Co said adjusted EBITDA margin expanded over 900 basis points due to improved product mix and cost management initiatives

  • CUSTOMER SPENDING - Co cited renewed spending in Q4 from a previously significant customer and expanding opportunities within key accounts

  • AI PLATFORM - Co said its scalable AI-enabled platform and proprietary healthcare data are competitive advantages supporting future growth


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Revenue

Beat

$21.60 mln

$21.19 mln (6 Analysts)

Q3 Adjusted EPS

Beat

$0.20

$0.17 (6 Analysts)

Q3 Adjusted Net Income

Beat

$3.80 mln

$3.21 mln (5 Analysts)

Q3 Adjusted EBITDA

Beat

$6.30 mln

$4.10 mln (6 Analysts)


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 6 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the online services peer group is "buy"

  • Wall Street's median 12-month price target for OptimizeRx Corporation is $11.00, about 17.6% above its November 10 closing price of $9.35

  • The stock recently traded at 9 times the next 12-month earnings vs. a P/E of 6 three months ago


Reuters Recommended Reads

  • Nov 9 - Trade Desk Q3 revenue beats analyst estimates

  • Nov 9 - Virtus Investment Partners Q3 adjusted EPS beats estimates

  • Nov 9 - ImmunityBio Q3 revenue rises on Anktiva sales growth but misses estimates


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.